MDM2 antagonist clinical response association with a gene expression signature in acute myeloid leukaemia
about
Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia.Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.Pharmacological activation of wild-type p53 in the therapy of leukemia.Acute myeloid leukemia patients' clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts.Predictive gene signatures determine tumor sensitivity to MDM2 inhibition.
P2860
MDM2 antagonist clinical response association with a gene expression signature in acute myeloid leukaemia
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 April 2015
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
MDM2 antagonist clinical respo ...... ure in acute myeloid leukaemia
@en
MDM2 antagonist clinical respo ...... re in acute myeloid leukaemia.
@nl
type
label
MDM2 antagonist clinical respo ...... ure in acute myeloid leukaemia
@en
MDM2 antagonist clinical respo ...... re in acute myeloid leukaemia.
@nl
prefLabel
MDM2 antagonist clinical respo ...... ure in acute myeloid leukaemia
@en
MDM2 antagonist clinical respo ...... re in acute myeloid leukaemia.
@nl
P2093
P2860
P356
P1476
MDM2 antagonist clinical respo ...... ure in acute myeloid leukaemia
@en
P2093
David Geho
Fabian Birzele
Gwen Nichols
Helmut Burtscher
Laurent Essioux
Lin-Chi Chen
Lori Jukofsky
Lucia Himmelein
P2860
P304
P356
10.1111/BJH.13411
P407
P50
P577
2015-04-08T00:00:00Z